Home
/ Mylan
/ Competitors

Mylan Competitors and Similar CompaniesClear all

Amgen's competitors and similar companies include BioMarin Pharmaceutical and Cipla.

	Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.	BioMarin Pharmaceutical BioMarin develops and provides innovative biopharmaceuticals for serious diseases and medical conditions.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
Founding Date	Founding Date 1980	Founding Date 1997	Founding Date 1935
Type	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development genetics oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more	Locations San Rafael, US HQ Martínez, AR Crows Nest, AU Sao Paulo, BR Bogotá, CO Kronberg Im Taunus, DE Wanchai, HK see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more
Employees	Employees 25,200	Employees 3,0015% increase	Employees 27,764
Valuation ($)	Valuation ($) 170.4 b	Valuation ($) 13.3 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $36.8b (FY, 2025)	Revenue (est.) $3.2b (FY, 2025)	Revenue (est.) ₹277.1b (FY, 2026)
Cost of goods	Cost of goods $12b (FY, 2025)	Cost of goods $717.4m (FY, 2025)	Cost of goods ₹95.5b (FY, 2026)
Gross profit	Gross profit $24.7b (FY, 2025)	Gross profit $2.5b (FY, 2025)	Gross profit ₹195b (FY, 2026)
Net income	Net income $7.7b (FY, 2025)	Net income $348.9m (FY, 2025)	Net income ₹38.7b (FY, 2026)
Operating ⚠
Phase III Trials Products	Phase III Trials Products 11 (FY, 2020)	Phase III Trials Products 2 (FY, 2016)	Phase III Trials Products N/A